Skip to main content
. 2020 May 26;11(21):1953–1960. doi: 10.18632/oncotarget.27602

Table 4. EGFR mutation subtypes .

Exon Mutation Subtype N (%) Stage at Presentation
Exon 19 deletion 63 (44) Stage 1 = 48 (76%)
Stage 2 = 7 (11%)
Stage 3 = 8 (13%)
Exon 20 insertion 7 (5) Stage 1 = 4 (57%)
Stage 2 = 0 (0%)
Stage 3 = 3 (43%)
G719A 2 (1) Stage 1 = 2 (100%)
Stage 2 = 0 (0%)
Stage 3 = 0 (0%)
L858R 49 (35) Stage 1 = 34 (70%)
Stage 2 = 5 (10%)
Stage 3 = 10 (20%)
G719× 6 (4) Stage 1 = 6 (100%)
Stage 2 = 0 (0%)
Stage 3 = 0 (0%)
L861Q 8 (6) Stage 1 = 7 (88%)
Stage 2 = 0 (0%)
Stage 3 = 1 (12%)
T790M 2 (1) Stage 1 = 2 (100%)
Stage 2 = 0 (0%)
Stage 3 = 0 (0%)
Multiple mutations 5 (4) Stage 1 = 4 (80%)
Stage 2 = 1 (20%)
Stage 3 = 0 (0%)